HomeCompareCNCE vs PEP

CNCE vs PEP: Dividend Comparison 2026

CNCE yields 23.89% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $49.5K in total portfolio value· pulled ahead in Year 9
10 years
CNCE
CNCE
● Live price
23.89%
Share price
$8.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$92.5K
Annual income
$10,014.51
Full CNCE calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — CNCE vs PEP

📍 PEP pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNCEPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNCE + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNCE pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNCE
Annual income on $10K today (after 15% tax)
$2,031.06/yr
After 10yr DRIP, annual income (after tax)
$8,512.33/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $44,081.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNCE + PEP for your $10,000?

CNCE: 50%PEP: 50%
100% PEP50/50100% CNCE
Portfolio after 10yr
$117.2K
Annual income
$35,945.10/yr
Blended yield
30.67%
📊

Analyst Conviction Gap

Where Wall Street is split right now

CNCE
Analyst Ratings
16
Buy
1
Hold
Consensus: Buy
Altman Z
2.4
Piotroski
1/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNCE buys
0
PEP buys
0
No recent congressional trades found for CNCE or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNCEPEP
Forward yield23.89%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$92.5K$141.9K
Annual income after 10y$10,014.51$61,875.67
Total dividends collected$57.3K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: CNCE vs PEP ($10,000, DRIP)

YearCNCE PortfolioCNCE Income/yrPEP PortfolioPEP Income/yrGap
1$13,089$2,389.49$10,849$509.42+$2.2KCNCE
2$16,929$2,923.10$11,969$750.47+$5.0KCNCE
3$21,647$3,533.17$13,500$1,124.14+$8.1KCNCE
4$27,385$4,222.32$15,680$1,721.66+$11.7KCNCE
5$34,294$4,992.02$18,929$2,715.34+$15.4KCNCE
6$42,537$5,842.50$24,023$4,450.80+$18.5KCNCE
7$52,287$6,772.75$32,510$7,669.92+$19.8KCNCE
8$63,728$7,780.57$47,709$14,093.60+$16.0KCNCE
9← crossover$77,051$8,862.62$77,415$28,083.48$364.00PEP
10$92,459$10,014.51$141,922$61,875.67$49.5KPEP

CNCE vs PEP: Complete Analysis 2026

CNCEStock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Full CNCE Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this CNCE vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNCE vs SCHDCNCE vs JEPICNCE vs OCNCE vs KOCNCE vs MAINCNCE vs MOCNCE vs PMCNCE vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.